Refine by
Vaccine Production Articles & Analysis
46 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
The BOC Sciences team will showcase its cutting-edge products and services at booth #937. TIDES USA 2024 is to be held in Boston from May 14 to 17, 2024, gathering industry leaders across the biotechnology and pharmaceutical landscape. ...
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. ...
Our bioproduction technology will help mass produce long, GMP-grade mRNA in a cost-efficient and scalable fashion by leveraging processes in engineered living cells. By bringing down the production cost of mRNA and simplifying the supply chain to make it local and more resilient, bYoRNA will help make mRNA vaccines available to the population of emerging ...
After years of efforts on research and innovation, we are now able to provide a wide range of vaccine development services as well, in addition to a diversified offering of vaccine products,” said the marketing chief of Alfa Chemistry. The featured vaccine products supplied by Alfa Chemistry are listed as below: ...
Nuvonis is providing 100 MCB vials to its clients allowing for production of very large quantities of WCB vials. Out of one MCB vial, 500 – 1,000 vials of WCB cells can be easily produced (Fig.). ...
ByNuvonis
Viral vaccine manufacturing is a complex venture with the main steps being antigen production, purification and formulation. ...
ByNuvonis
Analysis by Airfinity shows between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity. Airfinity’s risk analysis uses cumulative peak cases and deaths from Hong Kong's BA.1 wave as a proxy for mainland China. Hong Kong took a zero-COVID approach for the first two years of the ...
Tune into this free webinar to learn about: AAV biology and its use in cell and gene therapies State-of-the-art production of cell and gene therapies Current process intensification methods: cell line and vector engineering, media optimization, and bioreactor design to increase yields New strategies to properly attenuate anti-viral defences in the ...
In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and commercialisation of ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
The low cost and scalability of Lumen’s production platform, coupled with easy, needle-free administration, could greatly expand real-world access to malaria vaccines. ...
Having proven our capability, we now take this next important step as we aim to drive production of Element i+® analyzers and cartridges at scale and to accelerate key test menu expansion, such as our recently announced Nu.Q® Vet Cancer Screen, cCRP, SDMA, infectious diseases, and more, in single and multi-plex formats that are substantially better than the competition. ...
In the double-blind, randomized Phase 2 trial, 145 subjects ages 19.5-82.5 years received one of three formulations of the personalized dendritic cell-lymphocyte product, then were assessed for safety and cellular response. All three formulations of the vaccine were well-tolerated with no high-grade or serious adverse events reported. ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the ...
AAV vectors are the delivery vehicle of choice for inserting therapeutic genes into cells, but increasing production yields of these biopharmaceuticals in sufficient quantities to meet demand is challenging. ...
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer ...
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...